PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Input Field |
Entered |
SERIAL NUMBER | 90062733 |
---|---|
LAW OFFICE ASSIGNED | LAW OFFICE 115 |
MARK SECTION | |
MARK | VYCEUM (see, http://uspto.report/TM/90062733/mark.png) |
STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | VYCEUM |
OWNER SECTION (current) | |
NAME | Eli Lilly and Company |
MAILING ADDRESS | Lilly Corporate Center |
CITY | Indianapolis |
STATE | Indiana |
ZIP/POSTAL CODE | 46285 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
PHONE | 317-651-1346 |
FAX | 317 276 1919 |
XXXX | |
OWNER SECTION (proposed) | |
NAME | Eli Lilly and Company |
MAILING ADDRESS | Lilly Corporate Center |
CITY | Indianapolis |
STATE | Indiana |
ZIP/POSTAL CODE | 46285 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
PHONE | 317-651-1346 |
FAX | 317 276 1919 |
XXXX | |
CORRESPONDENCE INFORMATION (current) | |
NAME | BRUCE W. LONGBOTTOM |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | trademarks@lilly.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | longbottom_bruce@lilly.com |
CORRESPONDENCE INFORMATION (proposed) | |
NAME | Bruce W. Longbottom |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | trademarks@lilly.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | longbottom_bruce@lilly.com |
GOODS AND/OR SERVICES SECTION | |
INTERNATIONAL CLASS | 005 |
CURRENT IDENTIFICATION | Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases; Diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases |
GOODS OR SERVICES | KEEP ALL LISTED |
EXTENSION SECTION | |
EXTENSION NUMBER | 1 |
ALLOWANCE MAIL DATE | 02/02/2021 |
STATEMENT OF USE | NO |
PAYMENT SECTION | |
NUMBER OF CLASSES | 1 |
SUBTOTAL AMOUNT [EXTENSION FEE] | 125 |
TOTAL AMOUNT | 125 |
SIGNATURE SECTION | |
SIGNATURE | /blongbottom/ |
SIGNATORY'S NAME | Bruce W. Longbottom |
SIGNATORY'S POSITION | Assistant General Counsel |
DATE SIGNED | 06/30/2021 |
SIGNATORY'S PHONE NUMBER | 317 651 1346 |
SIGNATURE METHOD | Sent to third party for signature |
FILING INFORMATION | |
SUBMIT DATE | Wed Jun 30 15:48:14 ET 2021 |
TEAS STAMP | USPTO/ESU-XX.XXX.XXX.XX-2 0210630154814743914-90062 733-780b3f5d37ae9b27bbfc7 9e1a9b5dfcfff582164c2350a 6f04692e7c4ba4723a41-DA-4 8124201-20210630113853948 657 |
PTO- 1581 |
Approved for use through 03/31/2024. OMB 0651-0054 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |